Zosyn is a broad-spectrum intravenous antibiotic used to treat serious bacterial infections, including abdominal infections, pneumonia, skin infections, and gynecologic infections. It combines two active ingredients: piperacillin, which kills bacteria, and tazobactam, which prevents bacteria from disabling the antibiotic. This combination makes Zosyn effective against a wide range of organisms, including many that resist simpler antibiotics.
How Zosyn Works
Piperacillin belongs to the penicillin family. It kills bacteria by blocking their ability to build cell walls, which causes them to break apart and die. The problem is that many bacteria have learned to produce enzymes called beta-lactamases, which chew up penicillin-type drugs before they can work.
That’s where tazobactam comes in. It doesn’t kill bacteria on its own, but it neutralizes those protective enzymes, clearing the way for piperacillin to do its job. This pairing extends Zosyn’s reach to include beta-lactamase-producing strains of staph bacteria and many gram-negative organisms that would otherwise shrug off piperacillin alone.
Infections Zosyn Treats
Zosyn is approved for several categories of serious infection:
- Intra-abdominal infections, including peritonitis (infection of the abdominal lining), appendicitis, and gallbladder infections
- Pneumonia, both community-acquired and hospital-acquired (nosocomial) forms
- Skin and soft-tissue infections, including diabetic foot infections
- Gynecologic infections, such as pelvic inflammatory disease and postpartum uterine infections
It is also widely used in children for mixed infections involving both aerobic and anaerobic bacteria, particularly when Pseudomonas aeruginosa is suspected. Pseudomonas is a notoriously tough-to-treat bacterium common in hospital settings, and Zosyn’s activity against it is one of the main reasons clinicians reach for this drug over narrower antibiotics.
How Zosyn Is Given
Zosyn is given through an IV line, not by mouth. For most adult infections, the standard dose is 3.375 grams every six hours, infused over 30 minutes. Hospital-acquired pneumonia requires a higher dose of 4.5 grams every six hours, often paired with another class of antibiotic.
If your kidneys aren’t functioning well (a creatinine clearance of 40 mL/min or lower), the dose is reduced. Patients on hemodialysis typically receive a smaller dose every 12 hours, with an additional small dose after each dialysis session. Your medical team will adjust the dose based on lab work measuring kidney function.
For children, dosing is weight-based, generally 100 mg per kilogram of body weight given every eight hours for standard infections, or every six hours for severe ones.
Standard vs. Extended Infusion
Many hospitals now give Zosyn as an extended infusion, running it over three to four hours instead of the traditional 30 minutes. The reasoning is pharmacological: because piperacillin works best when its concentration stays above a certain threshold for as long as possible, a slower drip keeps blood levels in the effective range for more of each dosing interval.
A systematic review of ICU patients with pneumonia found that extended infusion shortened ICU stays by roughly two days compared to standard 30-minute infusions. Mortality and clinical cure rates trended better with extended infusion but didn’t reach statistical significance, meaning the advantage may be real but hasn’t been proven definitively. Side effect rates were similar between the two approaches. In practice, many hospitals have adopted extended infusion as their default protocol because there’s potential upside with no clear downside.
Common Side Effects
The most frequent side effects are digestive. In clinical trials, about 11% of patients experienced diarrhea, 8% had constipation, and 7% reported nausea. Headache (about 8%) and trouble sleeping (about 7%) were also common. When Zosyn is combined with another antibiotic class called aminoglycosides, diarrhea rates climb to around 20%.
These side effects are generally manageable and resolve once the antibiotic course ends. More serious but less common reactions include allergic responses ranging from rash to full anaphylaxis. Zosyn is off-limits if you have a known allergy to penicillins, cephalosporins, or beta-lactamase inhibitors. If you’ve ever had a reaction to amoxicillin, ampicillin, or similar drugs, make sure your care team knows before Zosyn is started.
Limitations Against Resistant Bacteria
One important limitation involves bacteria that produce extended-spectrum beta-lactamases, often called ESBLs. These are souped-up versions of the enzymes tazobactam is designed to block, and they can overwhelm it. Lab tests may show that an ESBL-producing organism is susceptible to Zosyn, but that result can be unreliable for several reasons.
The Infectious Diseases Society of America has flagged this as a concern. The ratio of tazobactam to piperacillin in each dose is 1:8, meaning there’s relatively little of the protective component compared to the antibiotic itself. In dense infections like abscesses, where bacterial counts are very high, ESBL-producing bacteria regrow significantly more often when treated with Zosyn compared to stronger alternatives. Bacteria carrying multiple resistance enzymes can further reduce tazobactam’s effectiveness. For confirmed ESBL infections, clinicians typically choose a different class of antibiotic rather than relying on Zosyn, even if lab susceptibility testing looks favorable.
This doesn’t diminish Zosyn’s role for the infections it handles well. It remains one of the most commonly used IV antibiotics in hospitals worldwide, particularly as initial empiric therapy when the exact organism hasn’t been identified yet and broad coverage is needed quickly.